Use of the heat shock protein gp96
CA 2415434 A1 · Owner: Immatics Biotechnologies Gmbh · Inventors: Schild, Hansjorg; Singh-Jasuja, Harpreet
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of gp96 molecules that carry no antigens of interest, for marking and/or activating antigen-presenting cells (APCs) for , example dendritic cells, monocytes macrophages, B cells and peritoneal , exudation cells. Said APCs can be loaded with antigens once they have been activated and are used to induce an immune response or in tumor therapy.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 9, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 9, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 9, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.